Around 5,000 NHS patients will now have full access to Orkambi, Symkevi and Kalydeco drugs which treat cystic fibrosis, following an agreement between Vertex Pharmaceuticals and NHS England. Health Secretary Matt Hancock hailed the news as a “very good deal” for taxpayers and patients. Report by Blairm. Like us on Facebook at http://www.facebook.com/itn and follow us on Twitter at http://twitter.com/itn